Clinical Trial Update: Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Zanzalintinib plus cemiplimab for BRAF wild-type anaplastic thyroid cancer; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anaplastic Thyroid Cancer | Phase 2 | Status: NOT_YET_RECRUITING